Ozan Şen1, Ahmet Gökhan Türkçapar2. 1. Türkçapar Bariatrics, Obesity Center, İstanbul, Turkey;Department of Health Sciences, Nişantaşı University, İstanbul, Turkey. 2. Türkçapar Bariatrics, Obesity Center, İstanbul, Turkey.
Abstract
BACKGROUND/AIMS: The aim of this study is to share the results of gastric botulinum toxin (BTX) application in individuals who are overweight or type 1 obese without comorbidity. MATERIALS AND METHODS: In this study, 13 patients were included who were enrolled for gastric BTX application for the first time. A total of 300 U of BTX-A (Allergan Botox ®1 vial 100 U) was diluted with 8 mL of 0.9% NaCl saline, and antrum (100 U to 8 spots), corpus (100 U to 8 spots), and fundus (100 U to 8 spots) regions were injected intramuscularly. Patients were given a 1200-calorie low-carb diet and this was followed for 6 months. RESULTS: Gastric BTX application was applied to 13 patients with a mean age of 40.9 ± 5.2 (85% female), a mean body mass index (BMI) of 28.41 ± 1.4 kg/m2 (26-31.6) and a mean excess weight of 10.1 ± 3.6 kg. As a result of the 6-month follow-up, only four patients (30.8%) were able to lose more than 50% of their excess weight (6-15 kg). Six patients (46.2%) could not lose any weight. There was an average decrease of 3.3 kg in the weight of patients before and after BTX application (P = .03). A mean decrease of BMI was detected, 1.17 kg/m2 (P = .032). CONCLUSION: It was concluded that the application of gastric BTX for weight loss does not provide effective results.
BACKGROUND/AIMS: The aim of this study is to share the results of gastric botulinum toxin (BTX) application in individuals who are overweight or type 1 obese without comorbidity. MATERIALS AND METHODS: In this study, 13 patients were included who were enrolled for gastric BTX application for the first time. A total of 300 U of BTX-A (Allergan Botox ®1 vial 100 U) was diluted with 8 mL of 0.9% NaCl saline, and antrum (100 U to 8 spots), corpus (100 U to 8 spots), and fundus (100 U to 8 spots) regions were injected intramuscularly. Patients were given a 1200-calorie low-carb diet and this was followed for 6 months. RESULTS: Gastric BTX application was applied to 13 patients with a mean age of 40.9 ± 5.2 (85% female), a mean body mass index (BMI) of 28.41 ± 1.4 kg/m2 (26-31.6) and a mean excess weight of 10.1 ± 3.6 kg. As a result of the 6-month follow-up, only four patients (30.8%) were able to lose more than 50% of their excess weight (6-15 kg). Six patients (46.2%) could not lose any weight. There was an average decrease of 3.3 kg in the weight of patients before and after BTX application (P = .03). A mean decrease of BMI was detected, 1.17 kg/m2 (P = .032). CONCLUSION: It was concluded that the application of gastric BTX for weight loss does not provide effective results.
Authors: Chang Seok Bang; Gwang Ho Baik; In Soo Shin; Jin Bong Kim; Ki Tae Suk; Jai Hoon Yoon; Yeon Soo Kim; Dong Joon Kim Journal: Gastrointest Endosc Date: 2015-03-09 Impact factor: 9.427
Authors: Mark Topazian; Michael Camilleri; Felicity T Enders; Jonathan E Clain; Ferga C Gleeson; Michael J Levy; Elizabeth Rajan; Vandana Nehra; Ross A Dierkhising; Maria L Collazo-Clavell; Nicholas J Talley; Matthew M Clark Journal: Clin Gastroenterol Hepatol Date: 2012-10-09 Impact factor: 11.382
Authors: Francisco José Sánchez-Torralvo; Luis Vázquez-Pedreño; Montserrat Gonzalo-Marín; María José Tapia; Fuensanta Lima; Eduardo García-Fuentes; Pilar García; Javier Moreno-Ruiz; Alberto Rodríguez-Cañete; Sergio Valdés; Gabriel Olveira Journal: J Clin Med Date: 2022-04-11 Impact factor: 4.241